Literature DB >> 2105749

Interaction of apolipoprotein A-II with recombinant HDL containing egg phosphatidylcholine, unesterified cholesterol and apolipoprotein A-I.

K A Rye1.   

Abstract

The preparation of discoidal, recombinant HDL (r-HDL) containing various phospholipids, apolipoproteins and a range of concentrations of unesterified cholesterol has been reported by several investigators. The present study describes the preparation of r-HDL containing both apolipoprotein (apo) A-I and apo A-II. r-HDL with 100:1 (mol:mol) egg PC.apo A-I and 0 (Series I), 5 (Series II) or 10 (Series III) mol% unesterified cholesterol were prepared by the cholate dialysis method. The resulting complexes had a Stokes' radius of 4.7 nm and contained two molecules of apo A-I per particle. When the r-HDL (2.0 mg apo A-I) were supplemented with 1.0 mg of apo A-II, one of the apo A-I molecules was replaced by two molecules of apo A-II. This modification was not accompanied by a loss of phospholipid, nor by major change in particle size. The addition of 2.5 or 4.0 mg of apo A-II resulted in the displacement of both apo A-I molecules from a proportion of the r-HDL and the formation of smaller particles (Stokes' radius 3.9 nm), which contained half the original number of egg PC molecules and three molecules of apo A-II. The amount of apo A-I displaced was dependent on the concentration of unesterified cholesterol in the r-HDL: when 2.5 mg of apo A-II was added to the Series I, II and III r-HDL, 44, 60 and 70%, respectively, of the apo A-I was displaced. Addition of 4.0 mg of apo A-II did not promote further displacement of apo A-I from any of the r-HDL. By contrast, the association of apo A-II with r-HDL was independent of the concentration of unesterified cholesterol and was a linear function of the amount of apo A-II which had been added. It is concluded that (1), the structural integrity of egg PC.unesterified cholesterol.apo A-I r-HDL, which contain two molecules of apo A-I, is not affected when one of the apo A-I molecules is replaced by two molecules of apo A-II; (2), when both apo A-I molecules are replaced by apo A-II, small particles which contain three molecules of apo A-II are formed; and (3), the displacement of apo A-I from r-HDL is facilitated by the presence of unesterified cholesterol in the particles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105749     DOI: 10.1016/0005-2760(90)90013-n

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?

Authors:  I C Gelissen; T Hochgrebe; M R Wilson; S B Easterbrook-Smith; W Jessup; R T Dean; A J Brown
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

2.  The HDL particle composition determines its antitumor activity in pancreatic cancer.

Authors:  Raimund Oberle; Kristina Kührer; Tamina Österreicher; Florian Weber; Stefanie Steinbauer; Florian Udonta; Mark Wroblewski; Isabel Ben-Batalla; Ingrid Hassl; Jakob Körbelin; Matthias Unseld; Matti Jauhiainen; Birgit Plochberger; Clemens Röhrl; Markus Hengstschläger; Sonja Loges; Herbert Stangl
Journal:  Life Sci Alliance       Date:  2022-05-16

3.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

Review 4.  Inhibition of Vascular Inflammation by Apolipoprotein A-IV.

Authors:  Kate Shearston; Joanne T M Tan; Blake J Cochran; Kerry-Anne Rye
Journal:  Front Cardiovasc Med       Date:  2022-06-30

5.  Inhibition of mitogen-activated protein kinase Erk1/2 promotes protein degradation of ATP binding cassette transporters A1 and G1 in CHO and HuH7 cells.

Authors:  Vishwaroop Mulay; Peta Wood; Melanie Manetsch; Masoud Darabi; Rose Cairns; Monira Hoque; Karen Cecilia Chan; Meritxell Reverter; Anna Alvarez-Guaita; Kerry-Anne Rye; Carles Rentero; Joerg Heeren; Carlos Enrich; Thomas Grewal
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.